NASDAQ$FULC
Fulcrum Therapeutics Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Provided a business update and reported financial results for the fourth quarter and full year of 2021.
Fulcrum Therapeutics reported collaboration revenue of $5.1 million for the fourth quarter of 2021, compared to $4.2 million for the fourth quarter of 2020. Research and development expenses were $18.9 million for the fourth quarter of 2021, as compared to $16.1 million for the fourth quarter of 2020. General and administrative expenses were $9.7 million for the fourth quarter of 2021, as compared to $5.9 million for the fourth quarter of 2020. Net loss was $23.5 million for the fourth quarter of 2021, as compared to a net loss of $17.7 million for the fourth quarter of 2020.
- Clear path forward for Phase 3 REACH trial with losmapimod in FSHD; Trial expected to begin in 2Q 2022
- On track to report initial data from Phase 1b trial with FTX-6058 in sickle cell disease in 2Q 2022
- Engaged with U.S. and EU regulatory agencies, including the Food and Drug Administration (FDA), and gained alignment on key aspects of the design for a Phase 3 trial with losmapimod for FSHD.
- Appointed Esther Rajavelu Fulcrum’s Chief Financial Officer in January 2022.
Headline financials
Revenue & EPS history
Fulcrum Therapeutics · Revenue · Quarterly
$5.06M
Forward guidance
Based on current plans, the company expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+5.2%
Avg return
Earnings day
+6.3%
Avg return
5 days after
+12.3%
Avg return
30 days after
62%
16 / 26 earnings
Positive
+142.5%
Q2 2021
Best reaction
-54.6%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -21.1% | -23.0% | -36.3% | |
| Q3 2025 | -6.6% | -9.8% | +9.4% | |
| Q1 2025 | +13.8% | +39.0% | +78.6% | |
| Q4 2024 | +0.0% | -3.0% | -16.5% | |
| Q3 2024 | -8.8% | -16.8% | +8.8% | |
| Q2 2024 | +7.1% | +0.6% | +1.7% | |
| Q1 2024 | +5.9% | +1.1% | +3.2% | |
| Q4 2023 | +6.1% | +12.9% | -3.0% | |
| Q3 2023 | +16.2% | -2.5% | +38.2% | |
| Q2 2023 | +3.4% | +5.5% | +49.7% | |
| Q1 2023 | +16.2% | -0.6% | -7.6% | |
| Q4 2022 | -28.0% | -36.6% | -62.0% | |
| Q3 2022 | +23.9% | +27.3% | +9.4% | |
| Q2 2022 | +8.4% | -6.2% | +7.1% | |
| Q1 2022 | -12.5% | -4.1% | -3.8% | |
| Q4 2021 | +17.4% | +37.8% | +113.9% | |
| Q3 2021 | -2.3% | -4.9% | -31.5% | |
| Q2 2021 | +142.5% | +175.3% | +233.9% | |
| Q1 2021 | +4.1% | +3.7% | -13.2% | |
| Q4 2020 | -17.7% | -17.4% | -17.8% | |
| Q3 2020 | +8.6% | +16.9% | +22.3% | |
| Q2 2020 | -54.6% | -55.5% | -54.7% | |
| Q1 2020 | +7.9% | +18.9% | +16.5% | |
| Q4 2019 | -2.2% | -27.8% | -49.4% | |
| Q3 2019 | +1.3% | +27.7% | +48.9% | |
| Q2 2019 | +7.2% | +6.1% | -25.5% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro